Am I a GLP-1 Non-Responder? How to Tell

You started a GLP-1 expecting the results you read about, and the scale is barely moving. It is a common and demoralizing situation. But “it isn’t working” and “I am a non-responder” are not the same statement. True non-response is a specific, relatively uncommon finding. Far more often, what looks like non-response is a slow start, a dose that hasn’t reached its working level yet, or a confounder in the background.

This piece walks through how clinicians actually define non-response, at what point it is fair to judge, and the fixable things to rule out first. Tracking the trend honestly is the whole game here, and a structured log (like our GLP-1 progress tracker) makes the difference between a real plateau and a misread far clearer. This is educational, not medical advice; the decision to change or stop a medication belongs to you and your prescriber.

What “non-responder” means

In the clinical literature, response is defined by a weight-loss threshold, and the common cutoff is 5% of baseline body weight. Someone who loses less than 5% over an adequate treatment period is usually described as a non-responder; the milestones above that are commonly 10%, 15%, and 20%.

The reassuring part is how uncommon true non-response is with the newer agents. In the STEP 1 trial of semaglutide 2.4 mg, 86.4% of participants lost at least 5% of their body weight, versus 31.5% on placebo. Higher thresholds were still reached by large fractions: about 69% lost 10% or more, and roughly 50% lost 15% or more. Reviews of the STEP program put the non-responder group (those losing under 5%) at roughly 10-17% of people, while a comparable third were “super-responders” losing more than 20%. Response varies a lot between individuals, but minimal response is the exception, not the rule.

In trials, a ‘non-responder’ is usually defined as losing less than 5% of body weight, and only about 10-17% of people on semaglutide fell into that group.

Response category	Weight loss from baseline	Roughly how common (STEP program)
Non-responder	< 5%	~10-17%
Responder	5-20%	majority
Super-responder	> 20%	~32-40%

The numbers above are for semaglutide. Dual-agonist tirzepatide trials usually show larger average losses, which tends to push an even higher share of people past the 5% line. The same “under 5%” definition applies, but true non-response appears even less often.

Judge response at a fair checkpoint

The single most common reason people wrongly label themselves non-responders is judging too early, on too low a dose. Both semaglutide and tirzepatide start at deliberately low “ramp-up” doses chosen for tolerability, not for weight loss. Expecting meaningful results at 0.25 mg semaglutide or 2.5 mg tirzepatide is judging the drug before it has started.

A fair assessment has two conditions:

• You have reached an effective maintenance dose, not a starter dose you are still titrating up from.
• You have held that dose long enough to see a trend, usually a few months, not a few weeks.

A useful reference point comes from the older GLP-1 liraglutide, whose labeling built in a formal check: reassess at 16 weeks, and if the person hasn’t lost a threshold amount of weight, the drug is unlikely to deliver worthwhile benefit and continuing is questioned. The exact number and timing differ by drug, but the principle is sound: response is judged at a defined checkpoint on an adequate dose, not on week-to-week scale noise. If you are still early in titration, you don’t have the information yet. Our companion piece on predicting who responds to GLP-1s covers the baseline factors that shift the odds.

Rule out the fixable causes first

Before concluding a drug has failed, it is worth ruling out the ordinary explanations that mimic non-response:

• Dose too low or titration stalled. If side effects, supply gaps, or caution kept you on a sub-maintenance dose, you haven’t tested the drug at its working level.
• Missed or mistimed injections. These are once-weekly drugs with steady-state kinetics; inconsistent dosing blunts the effect. Storage and injection-technique errors count here too.
• Genuine plateau vs. no response. Losing well and then stalling is a plateau, which is a different phenomenon with its own causes. We cover it in the GLP-1 weight-loss plateau explained. No movement from the start is what non-response looks like.
• Confounders. Weight-promoting medications (some antidepressants, steroids, certain antipsychotics), untreated thyroid disease, significant sleep loss, or a big change in circumstances can all mask real drug effect.
• The scale isn’t the whole picture. Early on, body composition and fluid shifts can hide fat loss. If the scale is flat but your waistband is looser, you may be responding in a way the scale doesn’t show.

Look beyond weight before deciding

Weight is the headline endpoint, but GLP-1s move other things too, and those can signal that the drug is working even when the scale lags. In the STEP 1 trial, semaglutide produced meaningful average improvements beyond weight: waist circumference fell substantially more than on placebo, systolic blood pressure dropped, and inflammatory and glycemic markers improved. If your blood pressure, A1c, or waist measurement are moving in the right direction, that is evidence of a metabolic response worth weighing before you conclude nothing is happening. Our guide on what metabolic markers to track on a GLP-1 lays out which numbers to watch.

What to do if you might genuinely be a non-responder

If you have reached an effective maintenance dose, held it consistently for several months, ruled out confounders, and there is no meaningful change in weight or the metabolic markers above, then it is reasonable to raise true non-response with your prescriber. That conversation might lead to switching agents (for example, from a single GLP-1 to a dual agonist), re-examining dose, or reassessing the plan entirely. It is a clinical decision, not a self-diagnosis, and stopping abruptly on your own carries its own downsides.

The takeaway

“Non-responder” is a real category, but a narrow one: under 5% weight loss on an adequate dose held long enough to judge. That description fits only about one in six to one in ten people on semaglutide. Before you claim it, make sure you have given the drug a fair test at a real maintenance dose, ruled out missed doses and confounders, and looked past the scale at your metabolic markers. Log the trend honestly with our GLP-1 progress tracker, and bring that record to your prescriber. A clear picture of what has and hasn’t moved is the best foundation for deciding what comes next.

Sources

• STEP 1 Trial (American College of Cardiology)
• STEP 1 once-weekly semaglutide (WikiJournalClub)
• Semaglutide for weight loss: unanswered questions (Frontiers in Endocrinology, 2024)
• Saxenda (liraglutide) FDA prescribing information — 16-week response assessment (drug label; specific URL not linked)